£430,000 is being ploughed into new drug testing to prevent heart disease in diabetics.
Manchester based researchers are going to lead a national trial for a drug which removes excess copper from diabetics which results in enhanced functioning of the heart.
The J P Moulton Charitable Foundation has given the £430,000 funding for phase 2B of the trials.
The University of Manchester's School of Biomedicine's Professor Paul Bishop is going to lead the trial, alongside colleagues from Manchester Royal Infirmary.
Preliminary studies have highlighted that the drug trientine, costing a few pence to manufacture per tablet, can keep diabetes -related complications at bay.
Excess copper can accumulate in tissues in diabetics which the Manchester research team has proven leads to heart damage.
Trientine sticks to the excess copper and enables it to safely leave the body, preventing more damage, even enabling damaged heart muscle to regenerate.
Funding of Drug Testing for Prevention of Heart Disease among Diabetics
Tue, 20 Dec 2011
Recommended links
Diabetic Health Insurance for a Single PersonDiabetic Health Insurance for a Couple
Diabetic Health Insurance for a Family
Diabetic Health Insurance for a Single Parent
Heart Disease
Clinical Trials for Diabetes
Diabetes Shop
What is covered by Diabetic Health Insurance
How Diabetes Private Medical Insurance Policies Work
Three Diabetics in American Law Suit against Employer
A Fifth of Indians are Diabetic
Tips for Diabetes Management
Body weight could offer early diabetes prediction before pregnancy
Insomnia Linked to Increased Insulin Resistance amongst Diabetics
ContentMain
